The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index.
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, aging, obesity and inflammation-related diseases such as diabetes and cardiovascular diseases have been shown to be risk factors for the severity of COVID-19 (293, 371–373).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [371]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · cited 1×
“Systemic inflammatory response syndrome, a common complication in severe COVID-19 [12], is promoted by the activation of CD14+ and”
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246 · cited 1×
“Preliminary data suggests that obesity may aggravate the severity of respiratory diseases and of COVID-19 [2].”
Self-citationAlberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597 · cited 1×
“hypertension and dyslipidemia were diagnosed based on established criteria.[10] All patients denied a history of chronic obstructive or restrictive pulmonary disease.”
BackgroundEslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472 · cited 2×
“[2] Patients with metabolic associated fatty liver disease (MAFLD),[3] formerly known as non-alcoholic fatty liver disease, are often obese and have additional metabolic risk factors which may translate to a greater risk from respiratory diseases.”
BackgroundMethodSelf-citationvan der Poorten, D., Milner, K., Hui, J. M., Hodge, A. D., Trenell, M. I., Kench, J. G., London, R. M., Peduto, T., Chisholm, D. J., & George, J. (2008) · Hepatology · doi:10.1002/hep.22350 · Cited by 611 · cited 2×
“[13] In MAFLD patients, particularly those with obesity, increased inflammatory activity in the liver and visceral fat is independently correlated with increased levels of IL-6,[14] which might have an additive/synergistic role in promoting greater severity of COVID-19.”
BackgroundSelf-citationCOVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies
Feng, G., Zheng, K. I., Yan, Q., Rios, R. S., Targher, G., Byrne, C. D., Poucke, S. V., Liu, W., & Zheng, M. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00018 · Cited by 422 · cited 1×
“This suggests IL-6 is a key proinflammatory factor that triggers the inflammatory “storm” in patients.[13] In MAFLD patients, particularly those with obesity, increased inflammatory activity in the liver and visceral fat is independently correlated with increased levels of IL-6,[14] which might have an additive/synerg…”
BackgroundSelf-citationObesity Is a Risk Factor for Greater COVID-19 Severity
Gao, F., Zheng, K. I., Wang, X.-B., Sun, Q.-F., Pan, K.-H., Wang, T.-Y., Chen, Y.-P., Targher, G., Byrne, C., George, J., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0682 · Cited by 376 · cited 1×
“for severe COVID-19 with a dose-effect relationship between increasing BMI and the proportion of patients with severe illness.[11] In the current analysis, the risk of severe illness in MAFLD patients with co-existing obesity was more than 6-fold greater after adjustment for confounders.”
BackgroundSelf-citationLean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation
Chen, F., Esmaili, S., Rogers, G. B., Bugianesi, E., Petta, S., Marchesini, G., Bayoumi, A., Metwally, M., Azardaryany, M. K., Coulter, S., et al. (2019) · Hepatology · doi:10.1002/hep.30908 · Cited by 338
Self-citationNseir, W., Mograbi, J., Amara, A., Abu-Elheja, O., & Mahamid, M. (2018) · QJM : monthly journal of the Association of Physicians · doi:10.1093/qjmed/hcy227 · Cited by 47 · cited 1×
“[4] [5] [6] [7] It is currently not known whether MALFD patients are also more likely to have greater COVID-19 severity of illness.”
Nonalcoholic fatty liver disease is associated with decreased lung function
Lee, C.-H., Choi, S.-H., Chung, G., Park, B., & Kwak, M.-S. (2018) · Liver international (Print) · doi:10.1111/liv.13860 · Cited by 36 · cited 1×
“[4] [5] [6] [7] It is currently not known whether MALFD patients are also more likely to have greater COVID-19 severity of illness.”
Cited by
Sorted by citations
Items 101–200 of 320
Actualización en COVID-19 y enfermedad hepática
Téllez, L., & Mateos, R. M. (2020) · Gastroenterology & hepatology · doi:10.1016/j.gastrohep.2020.06.006 · Cited by 36
Metabolic syndrome and COVID-19
Matias, J. N., Campanari, G. S. D. S., de Souza, G. A., Lima, V. M., Tofano, R. J., Detregiachi, C. R. P., & Barbalho, S. (2020) · AIMS Bioengineering · doi:10.3934/bioeng.2020021 · Cited by 34
Risk of infection and hospitalization by Covid-19 in Mexico: a case-control studyPreprint
Berumen-Campos, J., Schmulson, M. J., Alegre-Díaz, J., Guerrero, G., Oláiz, G., Wong‐Chew, R. M., Larriva-Sahd, J. A., Cantú-Brito, C. G., Ochoa-Guzmán, A., Garcilazo‐Ávila, A., et al. (2020) · medRxiv · doi:10.1101/2020.05.24.20104414 · Cited by 29
“in which obesity remained a significant risk factor even after adjusting for age, sex, smoking, diabetes, HBP, and dyslipidemia.(8) However, the fact that in Mexico obesity was less important than other risk factors for hospitalization, is somewhat different than other reports.”
BackgroundResultLiver dysfunction and SARS-CoV-2 infection
Gracia‐Ramos, A. E., Jáquez-Quintana, J. O., Contreras-Omaña, R., & Aurón, M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i26.3951 · Cited by 35
Resisting the problematisation of fatness in COVID-19: In pursuit of health justice
Pausé, C., Parker, G., & Gray, L. (2021) · International Journal of Disaster Risk Reduction · doi:10.1016/j.ijdrr.2020.102021 · Cited by 43
SARS-CoV-2-host dynamics: Increased risk of adverse outcomes of COVID-19 in obesity
Yadav, R., Aggarwal, S., & Singh, A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.07.030 · Cited by 36
Vrsaljko, N., Šamadan, L., Višković, K., Mehmedović, A., Budimir, J., Vince, A., & Papić, N. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac073 · Cited by 31
“In contrast, a small retrospective study from China (n = 66) showed a 6-fold increased risk of severe COVID-19 in obese NAFLD patients [19].”
Anti-inflammatory adipokines: chemerin, vaspin, omentin concentrations and SARS-CoV-2 outcomes
Kukla, M., Menżyk, T., Dembiński, M., Winiarski, M., Garlicki, A., Bociąga‐Jasik, M., Skonieczna, M., Hudy, D., Maziarz, B., Kuśnierz‐Cabala, B., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00928-w · Cited by 34
Cytokine Storm of COVID-19 and its Impact on Patients with and without Chronic Liver Disease
Premkumar, M., & Kedarisetty, C. K. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00055 · Cited by 37
Hill, M. A., Sowers, J. R., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154408 · Cited by 35
“Another study reported that the presence of fatty liver (metabolic associated fatty liver disease), another condition associatedwith excess body and visceral fat as determined by CT scans, was associated with a more severe clinical course for Covid-19 infection [29].”
BackgroundLubrano, C., Masi, D., Risi, R., Balena, A., Watanabe, M., Mariani, S., & Gnessi, L. (2020) · Obesity · doi:10.1002/oby.23000 · Cited by 32
Palomar-Lever, A., Barraza, G., Galicia‐Alba, J., Echeverri‐Bolaños, M., Escarria‐Panesso, R., Padua‐Barrios, J., Halabe-Cherem, J., Hernández-Molina, G., Chargoy‐Loustaunau, T. N., & Kimura-Hayama, E. (2020) · JGH Open · doi:10.1002/jgh3.12395 · Cited by 30
Fat mass affects nutritional status of ICU COVID-19 patients
LORENZO, A. D., Tarsitano, M. G., Falcone, C., Renzo, L. D., Romano, L., Macheda, S., Ferrarelli, A., Labate, D., Tescione, M., Bilotta, F., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02464-z · Cited by 33
COVID-19: the endocrine opportunity in a pandemic
Chatterjee, S., Ghosh, R., Biswas, P., Dubey, S., Guria, R. T., Sharma, C. B., & Kalra, S. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03216-2 · Cited by 41
Hussain, A., Vasas, P., & El-Hasani, S. (2020) · Metabolism: Clinical and Experimental · doi:10.1016/j.metabol.2020.154256 · Cited by 28
Obesity and COVID ‐19: A jigsaw puzzle with still missing pieces
Michalakis, K. G., Panagiotou, G., Ilias, Ι., & Pazaitou‐Panayiotou, K. (2020) · Clinical Obesity · doi:10.1111/cob.12420 · Cited by 29
“Obesity favours mechanisms that apply both to innate immunity and in the development of infection, which might partly explain why patients with obesity are more prone to suffer from respiratory infec- tions in the context of COVID-19.”
ResultInfluentialKottlors, J., Zopfs, D., Fervers, P., Bremm, J., Abdullayev, N., Maintz, D. C., Tritt, S., & ten Persigehl, T. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.109274 · Cited by 32
MAFLD in COVID-19 patients: an insidious enemy
Dongiovanni, P., Meroni, M., Longo, M., & Fracanzani, A. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1801417 · Cited by 27
Obesity and the increased risk for COVID-19: mechanisms and nutritional management
Morais, A. H. D. A., Passos, T. S., Vale, S. H. D. L., da Silva-Maia, J. K., & Maciel, B. L. L. (2020) · Nutrition Research Reviews · doi:10.1017/s095442242000027x · Cited by 40
“A mouse model of diet-induced obesity showed increased ACE2 expression in the lungs by the suppression of genes that encode SREBP1 Zheng et al.(118) Human case–control study MAFLD A multi-centre study involving 214 patients with laboratory-confirmed COVID-19 aged between 18 and 75 years of three hospitals in the city…”
BackgroundInfluentialSimons, D., Shahab, L., Brown, J., & Perski, O. (2020) · Qeios · doi:10.32388/ujr2aw.9 · Cited by 3
COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence
Idalsoaga, F. J., Ayares, G., Arab, J. P., & Díaz, L. A. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00140 · Cited by 29
“[105] Zheng KI, Gao F, Wang XB, Sun QF, Pan KH, Wang TY, et al.”
BackgroundEndocrine and metabolic complications of COVID-19: lessons learned and future prospects
Esmaeilzadeh, A., Elahi, R., Siahmansouri, A., Maleki, A. J., & Moradi, A. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0036 · Cited by 27
Srivastava, A., Greenberg, C. R., Sareen, N., Lionetti, V., & Dhingra, S. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04396-2 · Cited by 25
Liver disease and COVID-19: The link with oxidative stress, antioxidants and nutrition
Ristić-Medić, D., Petrović, S., Arsić, A., & Vučić, V. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i34.5682 · Cited by 27
Mostaghim, A., Sinha, P., Bielick, C. G., Knudsen, S., Beeram, I. R., White, L. F., Apovian, C. M., Sagar, M., & Hochberg, N. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243888 · Cited by 37
Fouad, Y., Saad, Z., Abdelraheem, E. M., Gany, Y. A., Moness, H., Osman, N., Abdelhameed, W., Mostafa, A., & Attia, D. (2020) · medRxiv · doi:10.1101/2020.08.20.20176214 · Cited by 23
Liver Injury and Elevated FIB-4 Define a High-Risk Group in Patients with COVID-19
Crișan, D., Avram, L., Grapa, C. M., Dragan, A., Rădulescu, D., Crişan, S., Grosu, A. I., Militaru, V., Buzdugan, E., Stoicescu, L., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010153 · Cited by 23
“Globally, MAFLD prevalence is estimated at 24% of the population [34] and in COVID-19 patients, its prevalence is approximately 30% [35].”
BackgroundAlarmins, COVID-19 and comorbidities
Salvo, E. D., Gioacchino, M. D., Tonacci, A., Casciaro, M., & Gangemi, S. (2021) · Annals medicus · doi:10.1080/07853890.2021.1921252 · Cited by 22
“These effects are particularly enhanced in patients with comorbidity such as lung fibrosis [22], obesity, non-alcoholic fatty liver disease [23], diabetes [24] in which alarmins play an important role.”
BackgroundRajendran, R., Chathambath, A., Al-Sehemi, A. G., Pannipara, M., Unnikrishnan, M., Aleya, L., Raghavan, R., & Mathew, B. (2022) · Environmental science and pollution research international · doi:10.1007/s11356-022-19148-4 · Cited by 21
Does higher body mass index increase COVID-19 severity? A systematic review and meta-analysis
Chowdhury, A. I., Alam, M. R., Rabbi, M. F., Rahman, T., & Reza, S. (2021) · Obesity Medicine · doi:10.1016/j.obmed.2021.100340 · Cited by 26
COVID-19 and comorbidities of hepatic diseases in a global perspective
Ahmad, A., Ishtiaq, S. M., Khan, J. A., Aslam, R., Ali, S., & Arshad, M. I. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i13.1296 · Cited by 25
SARS-CoV-2 and Obesity: “CoVesity”—a Pandemic Within a Pandemic
Zakka, K. R., Chidambaram, S., Mansour, S., Mahawar, K. K., Salminen, P. T. P., Almino, R., Schauer, P. R., Kinross, J. K., Purkayastha, S., & Collaborative, O. B. O. T. P. (2021) · Obesity Surgery · doi:10.1007/s11695-020-04919-0 · Cited by 27
Chang, Y., Jeon, J., Song, T.-J., & Kim, J. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07370-x · Cited by 20
“In a Chinese multicenter retrospective registry study with 66 patients, it was also reported that patients with NAFLD and obesity also presented with severe complications of COVID-19 [38].”
BackgroundLaino, M. E., Ammirabile, A., Lofino, L., Lundon, D., Chiti, A., Francone, M., & Savevski, V. (2022) · Emergency Radiology · doi:10.1007/s10140-021-02008-y · Cited by 20
Zamani, F., Khoshkhoo, Z., Hosseini, S., Basti, A. A., & Azizi, M. (2022) · Journal of Food Measurement & Characterization · doi:10.1007/s11694-021-01278-x · Cited by 20
Viral Clearance Course of COVID-19 Outbreaks
Samrah, S. M., Al-Mistarehi, A.-H. W., Kewan, T. Z., Al-Khatib, S., Ibnian, A. M., Samrah, R. S., & Khassawneh, B. Y. (2021) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s302891 · Cited by 28
Coronavirus disease 2019 pandemic and alterations of body composition.
Cava, E., & Carbone, S. (2021) · Current opinion in clinical nutrition and metabolic care · doi:10.1097/mco.0000000000000740 · Cited by 20
Data sharing during COVID-19 pandemic: what to take away
Rios, R. S., Zheng, K. I., & Zheng, M. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1815533 · Cited by 28
“The results of this study revealed that there is a significant risk that the presence of obesity (even after adjusting for probable confounders) is related to severe outcomes on infected patients [23].”
BackgroundSelf-citationYin, X.-R., Han, G., Zhang, H., Wang, M.-R., Zhang, W., Gao, Y.-F., Zhong, M., Wang, X., Zhong, X.-Z., Shen, G., et al. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00057 · Cited by 20
Self-citationPrediction Models for COVID-19 Integrating Age Groups, Gender, and Underlying Conditions
Ashraf, I., Alnumay, W. S., Ali, R., Hur, S., Bashir, A. K., & Zikria, Y. B. (2021) · Computers, materials & continua/Computers, materials & continua (Print) · doi:10.32604/cmc.2021.015140 · Cited by 21
“The authors state that obesity significantly increases the risk of complicated respiratory disease and COVID-19 infection [84].”
BackgroundNon-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?
Dietrich, C. G., Geier, A., & Merle, U. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.367 · Cited by 22
Gastrointestinal Perspective of Coronavirus Disease 2019 in Children—An Updated Review
Assa, A., Benninga, M., Borrelli, O., Broekaert, I., de Carpi, J. M., Saccomani, M., Dolinsek, J., Mas, E., Miele, E., Thomson, M., et al. (2021) · Journal of Pediatric Gastroenterology and Nutrition - JPGN · doi:10.1097/mpg.0000000000003204 · Cited by 19
Chatterjee, A., Wu, G., Primakov, S., Oberije, C., Woodruff, H., Kubben, P., Henry, R., Aries, M., Beudel, M., Noordzij, P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249920 · Cited by 19
COVID-19 and Obesity: Epidemiology, Pathogenesis and Treatment
Zhu, X., Liu, Y., & Huang, K. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s285197 · Cited by 20
Hayat, U., Ashfaq, M., Johnson, L., Ford, R., Wuthnow, C., Kadado, K., Jurdi, K. E., Okut, H., Kilgore, W., Assi, M., et al. (2022) · Kansas journal of medicine · doi:10.17161/kjm.vol15.16522 · Cited by 18
Cedano, J., Corona, E. F., Gonzalez-Lara, M., Santana, M., Younes, I., Ayad, S., Kossack, A., Purewal, A., & Pullatt, R. C. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2020.1830516 · Cited by 19
García-Ordás, M., Arias, N., Benavides, C., García-Olalla, Ó., & Benítez-Andrades, J. (2020) · Healthcare · doi:10.3390/healthcare8040371 · Cited by 18
“Obesity has been observed in other studies as a risk factor, tripling the likelihood of severe condition from COVID-19 [30].”
BackgroundFukushima, T., Chubachi, S., Namkoong, H., Otake, S., Nakagawara, K., Tanaka, H., Lee, H., Morita, A., Watase, M., Kusumoto, T., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.07.014 · Cited by 19
“First, these patients were older O’Driscoll et al., 2021 ), smokers ( Shastri et al., 2021 ; World Health rganization, 2021 ), and obese ( Zheng et al., 2020 ).”
Moctezuma-Velázquez, P., Miranda-Zazueta, G., Ortiz-Brizuela, E., Garay-Mora, J. A., González-Lara, M., Tamez-Torres, K., Román-Montes, C., Díaz-Mejía, B. A., Pérez-García, E., Villanueva-Reza, M., et al. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-02933-x · Cited by 17
“[8] in 66 patients with MAFLD, obesity was associated with increased COVID-19 severity; however, since all patients had MAFLD determined by CT and the criteria described in 2020 [21], its prognostic role in terms of outcomes of interest could not be assessed.”
BackgroundMalavazos, A. E., Secchi, F., Basilico, S., Capitanio, G., Boveri, S., Milani, V., Dubini, C., Schiaffino, S., Morricone, L. F., Foschini, C., et al. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01173-w · Cited by 21
Mechanisms of Infection By SARS-CoV-2, Inflammation and Potential Links With the Microbiome
Aguirre‐García, M. M., Mancilla-Galindo, J., Paredes‐Paredes, M., Tiburcio, Á. Z., & Ávila‐Vanzzini, N. (2021) · Future Virology · doi:10.2217/fvl-2020-0310 · Cited by 12
“001), suggesting increased severity, although no correlation with the mortality rate was found [86].”
BackgroundJi, D., Zhang, M., Qin, E., Zhang, L., Xu, J., Wang, Y., Cheng, G., Wang, F., & Lau, G. (2020) · Metabolism: Clinical and Experimental · doi:10.1016/j.metabol.2020.154437 · Cited by 17
COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD
Chen, H., & Chen, Q. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72461 · Cited by 16
“MAFLD patients with coexisting obesity had a more than 6-fold increased risk of severe COVID-19 [101], and further studies indicated that the association of MAFLD with COVID-19 severity is independent of obesity or diabetes [102, 103].”
BackgroundKukla, M., Menżyk, T., Dembiński, M., Winiarski, M., Garlicki, A., Bociąga‐Jasik, M., Skonieczna, M., Hudy, D., Maziarz, B., Kuśnierz‐Cabala, B., et al. (2021) · Biomolecules · doi:10.3390/biom11101422 · Cited by 16
“As mentioned above, overweightness and obesity are scientifically proven risk factors of more severe course of COVID-19 and, in consequence, of its higher mortality [10,11].”
BackgroundCOVID-19 and obesity: the meeting of two pandemics
Brandão, S., Godoi, E., Cordeiro, L., Bezerra, C. S., Ramos, J. D. O. X., Arruda, G. V., & Lins, E. M. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000318 · Cited by 16
“The association of COVID-19 and obesity increased the risk for the severe form of the disease by up to three times, while this risk was six times greater in the presence of NAFLD (68).”
BackgroundInfluentialMetabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Suoh, M., Esmaili, S., Eslam, M., & George, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10731-0 · Cited by 15
Self-citationBuchynskyi, M., Kamyshna, I. I., Oksenych, V., Zavidniuk, N. H., & Kamyshnyi, O. (2023) · Viruses · doi:10.3390/v15051072 · Cited by 17
“, 2020 [72] [80,81,83] (3) China Retrospective cohort study, 214/66 Co-occurring obesity in patients with MAFLD was found to increase the risk of severe illness by over six times.”
BackgroundDegarege, A., Naveed, Z., Kabayundo, J., & Brett‐Major, D. M. (2022) · Pathogens · doi:10.3390/pathogens11050563 · Cited by 26
Non-Alcoholic Fatty Liver Disease and COVID-19–Two Pandemics Hitting at the Same Time
Vranic, L., Radovan, A., Poropat, G., Mikolasevic, I., & Milić, S. (2021) · Medicina · doi:10.3390/medicina57101057 · Cited by 15
“reported a six-fold increased risk of severe COVID-19 in the presence of obesity in NAFLD patients in the logistic regression model even after adjusting for age, sex, smoking, diabetes, hypertension, and dyslipidaemia [49].”
BackgroundLiu, H., Xin, J., Cai, S., & Jiang, X. (2021) · eLife · doi:10.7554/elife.64188 · Cited by 15
Involvement of the digestive system in COVID-19. A review
Segura, P. S., Lázaro, Y. A., Tapia, S. M., Chaves, T. C., & Domingo, J. J. S. (2020) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2020.06.004 · Cited by 15
COVID-19 and severity of liver diseases: Possible crosstalk and clinical implications
Imam, M. T., Almalki, Z. S., Alzahrani, A. R., Alghamdi, S., Falemban, A. H., Alanazi, I. M., Shahzad, N., Alrooqi, M. M., Jabeen, Q., & Shahid, I. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110439 · Cited by 14
“Acute hepatic injury was demonstrated in 15.4 % of 187 confirmed COVID-19 patients in Wuhan, China, along with characteristic GIT symptoms without clinically evident respiratory illnesses [61,62].”
InfluentialRisk of Severe COVID-19 Increased by Metabolic Dysfunction-associated Fatty Liver Disease
Tao, Z., Li, Y., Cheng, B.-Q., Zhou, T., & Gao, Y.-J. (2021) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001605 · Cited by 14
Changes in eating habits and lifestyle during COVID-19 curfew in children in Saudi Arabia
Hanbazaza, M. A., & Wazzan, H. (2021) · Nutrition Research and Practice · doi:10.4162/nrp.2021.15.s1.s41 · Cited by 18
“People who suffer from overweight or even obesity need more care during a pandemic [15,16].”
BackgroundLamadrid, P., Alonso‐Peña, M., Segundo, D. S., Arias, M., Crespo, J., & López‐Hoyos, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651728 · Cited by 12
“While obese women with DM2 have lower expression of ACE2 and TMPRSS2 than obese normoglycemic women, obese men with NASH show markedly higher levels of these genes (18), which may explain the higher risk of severe COVID-19 in these patients (29).”
BackgroundCai, H., Yang, L., Lu, Y.-F., Zhang, S.-Y., Ye, C., Zhang, X.-L., Yu, G.-D., Gu, J.-Q., Lian, J., Hao, S., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05818-0 · Cited by 14
“A recent study from Zhejiang, China, also showed that in patients with metabolism-associated fatty liver disease, obesity increases the risk of severe COVID-19 illness [36].”
BackgroundFarrell, R., O’Regan, R., O'Neill, E., Bowens, G., Maclellan, A., Gileece, A., Bradley, M., Smyth, C., Kelly, O., Hall, B., et al. (2020) · Irish Journal of Medical Science · doi:10.1007/s11845-020-02407-z · Cited by 14
Physicians’ Perspectives on COVID-19: An International Survey
Dima, A., Balaban, D. V., Jurcuț, C., Berza, I., Jurcut, R. O., & Jinga, M. (2020) · Healthcare · doi:10.3390/healthcare8030250 · Cited by 12
“Diabetes and obesity were also identified as negative prognosis factors for progression and mortality [22,23].”
BackgroundJayant, K., Reccia, I., Bachul, P. J., Al-Salmay, Y., Pyda, J. S., Podda, M., Pérez-Gutiérrez, A., Dor, F. J. M. F., Becker, Y. T., di Sabato, D., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194533 · Cited by 25
Development and validation of a predictive model of in-hospital mortality in COVID-19 patients
Velasco-Rodríguez, D., Alonso-Domínguez, J., Vidal-Laso, R., Láinez-González, D., García-Raso, A., Martín-Herrero, S., Herrero, A., Martínez-Alfonzo, I., Serrano-López, J., Jiménez-Barral, E., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247676 · Cited by 13
“Several factors have been correlated with higher mortality in these patients: older age [5–7], male gender [6, 8], arterial hypertension [8], diabetes [5, 8], smoking [8], obesity [7], cardiac and pulmonary pathology [5, 8], and lymphopenia [9].”
BackgroundAssociation of COVID-19 with hepatic metabolic dysfunction
Kumar, R., Kumar, V., Arya, R., Anand, U., & Priyadarshi, R. N. (2022) · World Journal of Virology · doi:10.5501/wjv.v11.i5.237 · Cited by 12
Liver Damage and COVID-19: At Least a “Two-Hit” Story in Systematic Review
Montori, M., Baroni, G. S., Santori, P., di giampaolo, C., Ponziani, F. R., Abenavoli, L., & Scarpellini, E. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45040199 · Cited by 10
“It is interesting to note that although the MAFLD definition includes conditions that, independently, are risk factors for worse COVID-19 evolution (e.g., obesity, type 2 diabetes), non-alcoholic fatty liver disease (NAFLD) (according to the traditional fatty liver disease definition, characterized by liver steatosis…”
BackgroundInfluentialAraújo, D. C., Veloso, A., Borges, K. B. G., & Ferriani, M. D. G. C. (2022) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2022.104835 · Cited by 19
Schaalan, M., Warda, A. E. A., Osman, S., Fathy, S., Sarhan, R., Boshra, M., Sarhan, N., Gaber, S., & Ali, A. M. (2022) · Viruses · doi:10.3390/v14030448 · Cited by 11
“Obesity with excess adiposity is evidenced to induce interruption of the equilibrium between pro-inflammatory and anti-inflammatory immune cells, with a predominance of the former [14].”
BackgroundDelayed SARS-CoV-2 Clearance in Patients with Obesity
Zhang, X., Lin, B., Yang, G., Liu, L.-G., Lu, J., Lu, Z., & Xue, Y. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s319029 · Cited by 11
“All the patients were Asian and obesity was defined as body mass index (BMI) ≥ 25 kg/m(2), according to the International Obesity Task Force.(16,17) The study was approved by the Ethics Committee of the Third People’s Hospital of Changzhou, according to the Declaration of Helsinki, 2013 (02A-A20200004).”
BackgroundMethodCampos-Varela, I., Villagrasa, A., Simón-Talero, M., Riveiro-Barciela, M., Ventura-Cots, M., Aguilera-Castro, L., Álvarez-López, P., Nordahl, E. A., Antón, A., Bañares, J., et al. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211016567 · Cited by 11
Afectación del aparato digestivo en la covid-19. Una revisión sobre el tema
Segura, P. S., Lázaro, Y. A., Tapia, S. M., Chaves, T. C., & Domingo, J. J. S. (2020) · Gastroenterology & hepatology · doi:10.1016/j.gastrohep.2020.06.004 · Cited by 11
Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease
Jeeyavudeen, M. S., Chaudhari, R. B., Pappachan, J. M., & Fouda, S. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i3.487 · Cited by 12
Ichikawa, T., Torii, S., Suzuki, H., Takada, A., Suzuki, S., Nakajima, M., Tampo, A., & Kakinoki, Y. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.05.010 · Cited by 10
Rao, G. K., Gowthami, B., Naveen, N. R., & Samudrala, P. K. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100063 · Cited by 14
“There is an increased risk of severity in COVID-19 patients with a BMI of >25 kg/m2 and fatty liver disease than in patients without obesity (Zheng et al., 2020).”
Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic
Ahmed, M., & Ahmed, M. H. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i17.4133 · Cited by 12
Vasques‐Monteiro, I. M. L., & Souza‐Mello, V. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i16.1738 · Cited by 10
Obesity and its implications for COVID-19 pandemic in South Africa
van Vollenstee, F. A., & van der Merwe, M. (2021) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v36i1.228 · Cited by 10
“4,11 (4) Restricted pulmonary function, residual capacity and reduced lung volumes, as a result of disproportionately high percentage allocation of total body oxygen towards respiratory function, evolve favourably with weight loss following bariatric surgery.”
BackgroundLeon, L. A. A., Coelho, W. L. D. C. N. P., Alves, A. D. R., Carneiro, V. C. D. S., Moreira, O. C., de Paula, V. S., Salvio, A. L., Duarte, L. A., Gutman, E. G., Fontes-Dantas, F. L., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072568 · Cited by 11
“Upon infection, the most common symptoms were cough, fever, and fatigue, as has been frequently reported among COVID-19 patients [35,47,48].”
BackgroundLiver function in COVID-19 infection
Przekop, D., Gruszewska, E., & Chrostek, L. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i12.1909 · Cited by 10
Mdzinwa, N., Voigt, M., van Rensburg, C. V., & Paruk, F. (2021) · South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde · doi:10.7196/samj.2021.v111i11.15938 · Cited by 9
COVID‐19, adaptative immune response and metabolic‐associated liver disease
Miele, L., Napodano, C., Cesario, A., Magistris, A. D., Pocino, K., Basile, U., Rapaccini, G. L., Gasbarrini, A., & Grieco, A. (2021) · Liver International · doi:10.1111/liv.15061 · Cited by 11
COVID-19 in African Countries versus other World Regions: A Review.
Kaba, A., & Kaba, A. N. (2020) · African Journal of Reproductive Health · doi:10.29063/ajrh2020/v24i2s.17 · Cited by 9
Liatsos, G. D. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i16.2397 · Cited by 10
COVID-19 and MAFLD/NAFLD: An updated review
Nowroozi, A., Momtazmanesh, S., & Rezaei, N. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1126491 · Cited by 8
“5 times more likely to acquire severe disease (52), Zheng and colleagues (53) demonstrated that in patients with MAFLD, obesity was associated with six times higher risk for severe COVID-19.”
BackgroundFursov, A., Ospanov, O., & Fursov, R. (2022) · Obesity and Metabolism · doi:10.14341/omet12745 · Cited by 8
Olszanecka‐Glinianowicz, M., Dudek, D., Filipiak, K. J., Krzystanek, M., Markuszewski, L., Ruchała, M. A., & Tomiak, E. (2020) · Nutrition Obesity & Metabolic Surgery · doi:10.5114/noms.2020.97921
What hepatologists need to know about COVID-19?
Yapalı, S. (2020) · Hepatology Forum · doi:10.14744/hf.2020.2020.0011 · Cited by 8
“The consent form should include the potential risk for nosocomial COVID-19.”
BackgroundInfluentialNadal, A., & Nazar-Beutelspacher, D. A. (2023) · Global Food Security · doi:10.1016/j.gfs.2023.100697 · Cited by 7
“In terms of health outcomes, chronic disease morbidity linked to food consumption high in sugar, salt and fat (diabetes, obesity, hypertension) is associated with severe COVID-19 disease (Dietz and Santos-Burgoa, 2020; Zheng et al., 2020).”
BackgroundValentino, M. S., Marzuillo, P., Esposito, C., Bartiromo, M., Nardolillo, M., Villani, A. V., Maresca, A., Furcolo, G., Guarino, S., del Giudice, E. M., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12052037 · Cited by 7
“In particular, an increased risk of severe COVID-19 illness more than sixfold has been found for adult patients with MAFLD [38].”
BackgroundCOVID-19-associated liver injury, role of drug therapy and management: a review
IHEANACHO, C. O., & Enechukwu, O. H. (2022) · Egyptian Liver Journal · doi:10.1186/s43066-022-00230-y · Cited by 7
Review of the Metabolic Risk Factors for Increased Severity of Coronavirus Disease-2019
Fishkin, T., Goldberg, M., & Frishman, W. (2021) · Cardiology in Review · doi:10.1097/crd.0000000000000408 · Cited by 7
Theise, N., Arment, A., Chakravarty, D., Gregg, J. M. H., Jacobson, I., Jung, K.-H., Nair, S., Tewari, A., Thurston, A., Drie, J. V., et al. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1859752 · Cited by 7
Sy-Janairo, M. L., & Cua, I. H. (2020) · JGH Open · doi:10.1002/jgh3.12465 · Cited by 7
Is lung density associated with severity of COVID-19?
Bressem, K., Adams, L. C., Albrecht, J., Petersen, A., Thieß, H.-M., Niehues, A., Niehues, S., & Vahldiek, J. (2020) · Polish Journal of Radiology · doi:10.5114/pjr.2020.100788 · Cited by 7
“One of these risk factors is obesity; it was shown that an increased body mass index or increased areas of visceral fatty tissue was associated with more severe COVID-19 [26,27].”
Background
Metadata
- Authors
- Zheng, K. I., Gao, F., Wang, X.-B., Sun, Q.-F., Pan, K.-H., Wang, T.-Y., Ma, H.-L., Chen, Y.-P., Liu, W.-Y., George, J., & Zheng, M.-H.
- Affiliations
- First Affiliated Hospital of Wenzhou Medical University (CN)
- The University of Sydney (AU)
- Wenzhou Medical University (CN)
- Corresponding author
- George, Jacob
- Zheng, Ming-Hua
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 108
- Pages
- 154244
- ISSN
- 0026-0495 (ISSN-L)
- PMC
- PMC7166301
- OpenAlex
- W3016610783
- Cited by
- 332
- References
- 14
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 10 · 2023: 28 · 2022: 44 · 2021: 101 · 2020: 140
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- The Sydney eScholarship Repository (The University of Sydney) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81500665)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- obesity, COVID-19 severity, metabolic-associated fatty liver disease, non-alcoholic fatty liver disease, comorbidities, SARS-CoV-2, disease severity risk factors, metabolic risk factors, respiratory disease risk, hypoxia, innate immunity, lung function, SARS-CoV-2 viral load, SARS-CoV-2 variants
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Obesity, Pneumonia, Viral, Risk Factors, Coronavirus Infections, Young Adult, Pandemics, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
